Calumet, Inc. <CLMT.O>: UBS Raises Target Price to $47 From $26
CLMT•Related News
Genmab executive team joins fireside chats at upcoming investor healthcare conferences
GMAB•
Schmid maintains 2026 revenue outlook at least EUR 100 million, cuts adjusted EBITDA margin forecast to 6%-9%
SHMD•
Real Messenger launches US$ 2 million share buyback program over two years
RMSG•
Nasdaq trade halt continues <UCFI.O> reason not available at 09:37 am
UCFI•
American Battery Materials extends note maturities to Sept. 30, 2026 with 15% principal step-up if NYSE American uplist missed
BLTH•